Inside Precision Medicine October 23, 2024
Laura Cowen

The U.S. National Institutes of Health has launched a unique portfolio of biomarker-driven precision medicine clinical trials, known as myeloMATCH, that will test new treatments for patients with myeloid cancers.

The patients will be enrolled in the trial from diagnosis through multiple stages of their treatment journey.

“MyeloMATCH provides a portfolio of biomarker-driven treatment trials that adult patients newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) will enroll to sequentially over their entire treatment journey,” said co-chair of myeloMATCH’s senior science council Harry Erba, MD, PhD of Duke University School of Medicine. “At each step along that journey, the goal is to continually reduce the patient’s tumor burden, to target residual disease more effectively, and ultimately cure...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Clinical Trials, Pharma / Biotech, Precision Medicine, Trends
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Bankruptcy, Genetic Information, and Privacy — Selling Personal Information
Quibim: $50M Series A for Precision Medicine with AI-Powered Imaging Biomarkers
How DNA and hormones shape who we are
Global Genetics Study of 1.7M People Finds New Depression Risk Variants

Share This Article